Brief: Orion Provides Positive Data From Darolutamide Studies
16/09/2024 10:07
Sept 16 (Reuters) - Orion Oyj ORNBV.HE :
* DAROLUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY
SIGNIFICANTLY
REDUCED THE RISK OF RADIOLOGICAL PROGRESSION OR DEATH BY 46%
COMPARED TO PLACEBO PLUS ADT IN PATIENTS WITH METASTATIC
HORMONE-SENSITIVE PROSTATE CANCER
* SAFETY ANALYSIS RECONFIRMS ESTABLISHED TOLERABILITY
PROFILE OF
DAROLUTAMIDE AS OBSERVED IN ARAMIS AND ARASENS TRIALS
* DAROLUTAMIDE PLUS ADT HAS POSITIVE DATA WITH AND WITHOUT
DOCETAXEL BASED ON TWO PIVOTAL PHASE III STUDIES IN METASTATIC
PROSTATE CANCER
* DAROLUTAMIDE PLUS ADT NOW HAS POSITIVE DATA BOTH WITH AND
WITHOUT DOCETAXEL BASED ON TWO PIVOTAL PHASE III STUDIES IN
METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Source text for Eikon: ID:nGNX5sYJrq
Further company coverage: ORNBV.HE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))